A phase II trial of oral etoposide with mitoxantrone and ifosfamide/mesna consolidated with intravenous etoposide, methylprednisolone, high-dose arabinoside, and cisplatin as salvage therapy for relapsing and/or refractory lymphomas

JorgeE.Romaguera; M.AlmaRodriguez; FrederickB.HagemeisterPeterMcLaughlinForrestSwanDennisF.MooreJr.AndreasH.SarrisAnasYounesDebbieHillFernandoCabanillas

首页> 外文期刊>investigational new drugs >A phase II trial of oral etoposide with mitoxantrone and ifosfamide/mesna consolidated with intravenous etoposide, methylprednisolone, high-dose arabinoside, and cisplatin as salvage therapy for relapsing and/or refractory lymphomas

【24h】

A phase II trial of oral etoposide with mitoxantrone and ifosfamide/mesna consolidated with intravenous etoposide, methylprednisolone, high-dose arabinoside, and cisplatin as salvage therapy for relapsing and/or refractory lymphomas

机译：

获取原文

开具论文收录证明 >>

AI期刊论文写作 >>

页面导航

著录项
引文网络
相似文献
相关主题

著录项

来源
《investigational new drugs》 |1994年第3期|217-222|共页
作者
JorgeE.Romaguera; M.AlmaRodriguez; FrederickB.HagemeisterPeterMcLaughlinForrestSwanDennisF.MooreJr.AndreasH.SarrisAnasYounesDebbieHillFernandoCabanillas;
展开▼
作者单位

The University of Texas M.D. Anderson Cancer Center;

展开▼
收录信息
原文格式 PDF
正文语种英语
中图分类
关键词

相似文献

外文文献
中文文献

1. A phase II trial of mesna/ifosfamide, mitoxantrone and etoposide for refractory lymphomas [J] . M. A.Rodriguez, F. C.Cabanillas, F. B.HagemeisterP.McLaughlinJ. E.RomagueraF.SwanW.Velasquez annals of oncology . 1994,第6期

机译：美司钠/异环磷酰胺、米托蒽醌和依托泊苷治疗难治性淋巴瘤的 II 期试验
2. A phase II study of dexamethasone, ifosfamide, cisplatin and etoposide (DICE) as salvage chemotherapy for patients with relapsed and refractory lymphoma. [J] . Biagi JJ, Herbert KE, Smith C, Leukemia and lymphoma . 2005,第2期

机译：地塞米松，异环磷酰胺，顺铂和依托泊苷（DICE）作为挽救性化疗用于复发性和难治性淋巴瘤患者的II期研究。
3. A multicenter phase II trial of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin for patients with primary refractory/relapsed aggressive non-Hodgkin’s lymphoma [J] . Sun Jin Sym, Dae Ho Lee, Hye Jin Kang, Cancer Chemotherapy and Pharmacology . 2009,第1期

机译：依托泊苷，甲基强的松龙，大剂量阿糖胞苷和奥沙利铂的多中心II期试验用于原发性难治性/复发性侵袭性非霍奇金淋巴瘤患者
4. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
5. Evaluation of a method for calculating carboplatin dosage in DeVIC ± R therapy (combination therapy of dexamethasone etoposide ifosfamide and carboplatin with or without rituximab) as a salvage therapy in patients with relapsed or refractory non-Hodgkin lymphoma [O] . Ayana Tomono, Kaori Ito, Takahiro Hayashi, -1

机译：评价DeVIC±R治疗（地塞米松依托泊苷异环磷酰胺和卡铂联合或不联合利妥昔单抗的联合治疗）中计算卡铂剂量作为挽救治疗的复发或难治性非霍奇金淋巴瘤患者
6. Double High Dose Salvage Therapy With Dose-Intensified Cyclophosphamide, Etoposide, and Cisplatin (DICEP) Re-Induction Followed by High-Dose Melphalan (HDM) and Autologous Stem Cell Transplantation (ASCT) Consolidation for Relapsed/Refractory Hodgkin Lymphoma [O] . Shafey M., Duan Q., Russell J.A., 2011

机译：双重大剂量挽救疗法，采用剂量增强的环磷酰胺，依托泊苷和顺铂（DICEP）再诱导，然后进行大剂量美法仑（HDM）和自体干细胞移植（ASCT）合并治疗复发/难治性霍奇金淋巴瘤

A phase II trial of oral etoposide with mitoxantrone and ifosfamide/mesna consolidated with intravenous etoposide, methylprednisolone, high-dose arabinoside, and cisplatin as salvage therapy for relapsing and/or refractory lymphomas

著录项

引文网络

相似文献

相关主题

期刊订阅